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Tbjectives: Aprotinin is a drug used to reduce bleeding in patients undergoing
ardiothoracic surgery with cardiopulmonary bypass. A recent cohort evaluation
ound elevated risks of renal, cardiovascular, and cerebrovascular events when
protinin was used. We sought to determine the impact of aprotinin on safety
ariables among patients receiving cardiothoracic surgery with cardiopulmonary
ypass from a single US hospital that reserves aprotinin for complex surgeries and
ehovah’s Witnesses and does not utilize celite-based activated clotting time deter-
inations.
ethods: We performed a cohort evaluation with multivariate logistic regression,
ncluding propensity score adjustment comprising patients from January 1, 2000 and
ecember 31, 2005. We evaluated 3348 patients having cardiothoracic surgery in a
ingle tertiary care medical center. We observed aprotinin use or lack of aprotinin
n cardiothoracic surgery. The main outcome measures were odds (expressed as an
dds ratio with 95% confidence interval) of developing myocardial infarction,
erebrovascular events, and renal dysfunction after cardiothoracic surgery between
roups.
esults: Patients receiving aprotinin were less likely to experience a cerebrovascular
vent compared with control [0.65 (0.46–0.91)] and did not have an elevated odds
f myocardial infarction [1.04 (0.53–2.04)] but were more likely to experience
ostoperative renal dysfunction [2.03 (1.37–3.01)].
onclusions: Aprotinin was not associated with negative myocardial or cerebrovas-
ular risks but did increase the risk of renal dysfunction. It is not known whether the
enal dysfunction reflects renal damage or a transient reduction in glomerular
ltration pressure.
ardiothoracic surgery (CTS) with cardiopulmonary bypass (CPB) induces
platelet dysfunction, thrombin production, and plasmin release.1,2 Bleeding
during or shortly after CTS is a common complication, resulting in trans-
usion, reexploration, or tamponade.3,4 Cardiac operations account for 10% of the 11
illion units of allogenic blood transfused in the United States annually and carry real but small risk of blood transfusion infection.4
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CSPAprotinin is a serine protease inhibitor derived from
ovine lung that attenuates thrombin generation, fibrinoly-
is, and inflammatory processes.3,4 In a multicenter, multi-
ational (23 countries), observational study involving 4374
atients having CTS, aprotinin use was associated with an
ncreased risk of renal dysfunction or renal failure among
atients receiving primary (odds ratio [OR] 2.34; 95% con-
dence interval [CI] 1.27-4.31) and complex CTS (OR 2.59,
5% CI 1.36-4.95) as compared with patients receiving no
reatment.5 The use of aprotinin was also associated with a
ignificant increase in the risk of cardiovascular (OR 1.42,
5% CI 1.09-1.86) and cerebrovascular events (OR 2.15,
5% CI 1.14-4.06) among patients having primary CTS but
ot among patients having complex CTS.
These results are in contrast to those of a meta-analysis
f randomized, placebo-controlled coronary artery bypass
raft (CABG) trials from 1988 to 2001 where aprotinin (35
rials, 3887 subjects) did not increase the risk of myocardial
nfarction (MI; relative risk [RR] 0.85, 95% CI 0.63-1.14),
enal failure (RR 1.01, 95% CI 0.55-1.83), or stroke (RR
.53, 95% CI 0.31-0.90) versus controls.6 Most trials in-
luded in the meta-analysis were comprised of patients
aving complex CTS.
The observational study utilized data from 23 countries,
nd the meta-analysis was constituted mostly of trials con-
ucted within the United States, which might account for
he differences. In the International Multicenter Aprotinin
raft Patency Experience (IMAGE) trial, patients from 13
nternational sites were randomized to receive aprotinin
n  436) or placebo (n  434).7 Among 703 patients with
ssessable saphenous vein grafts, 15.4% of patients treated
ith aprotinin and 10.9% of patients treated with placebo
ad occlusions. However, in the United States, occlusions
ccurred in 9.4% of patients receiving aprotinin and 9.5% of
atients receiving placebo (P  .72), and at Danish and
sraeli sites, the occlusions occurred in 23.0% of patients
eceiving aprotinin and 12.4% patients receiving placebo
P  .01).7,8
Neither the observational trial nor meta-analysis reported
verage doses of heparin between groups or what type of
Abbreviations and Acronyms
ACT  activated clotting time
CABG coronary artery bypass graft
CI  confidence interval
CPB  cardiopulmonary bypass
CTS  cardiothoracic surgery
MI myocardial infarction
OR  odds ratio
RR  relative risk
TIA  transient ischemic attackctivated clotting time (ACT) test was being used. Aproti- i
548 The Journal of Thoracic and Cardiovascular Surgery ● Junin induces a drug–lab test interaction with diatomaceous
arth-based ACTs (celite-ACT) resulting in abnormally
igh ACT values. Use of kaolin-based ACTs (kaolin-ACT)
r “sonoclot aprotinin insensitive ACTs” do not have the
ame interaction.3,9 Studies have found underdosing of hep-
rin when celite-ACTs are used with aprotinin, which may
ncrease the risk of cardiovascular, cerebrovascular, and
enal events versus control.3,10
Given the dichotomous findings and limitations of the
revious studies, we conducted a large cohort evaluation of
protinin use for CTS from a single US hospital that does
ot use celite-ACT determinations.
aterials and Methods
esign and Population
his was a cohort evaluation of all patients undergoing CTS at our
nstitution between January 1, 2000 and December 31, 2005. The
linical data were collected prospectively and entered in the clin-
cal database, but the aprotinin data and the analysis of the data
ccurred retrospectively. To be included in this evaluation, pa-
ients had to have undergone CABG surgery (either alone or with
alve or other surgery) and utilized a CPB pump. Patients meeting
he above criteria and using aprotinin comprised the treatment
roup, and those patients not utilizing aprotinin comprised the
ontrol group. Our institution’s aprotinin protocol requires aproti-
in to be dosed by either of the two Food and Drug Administra-
ion–approved regimens; however, the full-dose regimen is almost
xclusively used. The Hartford Hospital Institutional Review
oard approved this study with a waiver of informed consent.
ardiopulmonary Bypass Pump Management
nticoagulation was initiated with heparin 300 U/kg. The target
aolin-ACT before initiating the CPB pump was greater than 500
econds for aprotinin-treated patients and greater than 450 seconds
or non–aprotinin-treated patients. Kaolin-ACTs (Hemochron, ITC
orporation, Edison, NJ, and I-STAT, Abbott Point of Care, East
indsor, NJ) were taken at baseline, 5 minutes after initial hep-
rinization, after heparin dosage adjustments, and after protamine
eversal. During surgery, the threshold for transfusion was a he-
atocrit level below 18%. Pump flow rates ranged from 1.8 to 2.5
/min/m2 at 30°C to 32°C to 2.5 to 3.2 L/min/m2 at 34°C to 37°C.
n some patients, the depth of hypothermia was lowered to 20°C
nd determined via rectal probe. Cardioplegic solution for myo-
ardial protection was a 4:1 blood to crystalloid mix with added
nsulin and procaine. There was a high and low potassium cardiople-
ic solution with both solutions containing lactated Ringer’s, dex-
rose, sodium bicarbonate, and potassium chloride. Cardioplegic
olution was given antegrade and/or retrograde and given either
arm or cold.
rial End Points and Definitions
or the purposes of this study, the following definitions were used:
ll end points were monitored for from the time of surgery until
atient discharge. Renal dysfunction was defined as acute or wors-
ning renal failure resulting in 1 or more of the following: (1) an
ncrease in serum creatinine to 2.0 and twice the baseline creat-
nine level or (2) a new requirement for dialysis. MI was defined
e 2007
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CS
Ps perioperative MI, diagnosed by finding two of the following
riteria: (1) prolonged (20 minutes) typical chest pain not re-
ieved by rest and/or nitrates; (2) enzyme level elevation (either
reatine kinase M monomer/B monomer isoenzyme  5% of total
reatine kinase, creatinine kinase greater than twice normal, lactate
ehydrogenase subtype 1  lactate dehydrogenase subtype 2, or
roponin-T  0.2 g/mL); (3) new wall motion abnormalities; (4)
erial electrocardiograph (at least 2) showing changes from base-
ine or serially in ST-T and/or Q waves that are 0.03 seconds in
idth and/or greater or plus one third of the total QRS complex in
or more contiguous leads. Stroke was defined as central neuro-
ogic deficit persisting for 72 hours. Transient ischemic attack
TIA) was defined as transient neurologic deficit with recovery
ithin 24 hours. Delirium was defined as a definite state of
onfusion, agitation, or hallucination (auditory or visual) unrelated
o narcotics or anesthesia. Patients with baseline delirium were
nly counted if their state markedly worsened post-CTS. Cerebro-
ascular event was defined as occurrence of stroke, TIA, or delir-
um. Death was defined as death prior to hospital discharge. Red
lood cell requirement was defined as need for red blood cell
ransfusion. Reoperation due to bleeding was defined as operative
eintervention required for bleeding or tamponade.
Subgroup analysis was conducted to determine the impact of
urgical complexity on study safety and efficacy end points. In this
nalysis, only patients undergoing complex CTS (either repeat
TS or valvular involvement) were included in the analysis.
tatistical Analysis
ontinuous variables are presented as means with standard devi-
tions and were compared between groups using a Student t test.
ichotomous variables are presented as percentages and were
ompared between groups via 2 analysis.
As this was an observational study, the investigators had no
ontrol over which patients received aprotinin and which did not.
s a result, significant differences on important observed demo-
raphic and pre- and perioperative variables were likely to occur,
hich could lead to a biased estimate of treatment effect. There-
ore, we conducted multivariate logistic regression to control for
otential confounders in our evaluation. We first conducted uni-
ariate analysis to examine the association between the occurrence
f the end point of interest (dependant variable, renal failure, MI,
nd so on) and pre-, intra-, and postoperative variables (indepen-
ent variables). All variables with a P value of .2 in the univar-
ate analysis were entered into a multivariate logistic regression
odel. In addition, the propensity score, or the conditional prob-
bility of being treated with aprotinin based upon an individual’s
haracteristics, were calculated using 41 demographic and preop-
rative variables for each patient using logistic regression. The
iscriminate power of the propensity scores was quantified by
easurement of the receiver operating characteristic area (the
-index) and was found to be 0.85.
Upon their calculation, the raw propensity score was included
n overall multivariate logistic regression model in addition to
ariables qualifying for inclusion following univariate analysis. In
he multivariate model, variables were selected by stepwise, back-
ard elimination. Odds ratios and 95% CIs were calculated for allndependent predictors. Statistical analysis was performed with p
The Journal of ThoracicPSS version 11.0 (SPSS, Chicago, Ill) and R version 1.8.1 (The
Foundation for Statistical Computing, Vienna, Austria).
ample Size Calculation
ased upon the recent cohort analysis of aprotinin by Magano and
olleagues,5 it was determined that a total of 1114 patients would
e required to detect a 42% increase in patients’ risk of postoper-
tive MI using aprotinin compared with control, assuming a 13%
ncidence in the control group, an alpha of 0.05, and power of
0%. Moreover, based upon that same evaluation, it was deter-
ined that the above sample size should be sufficient to detect
tatistically significant increases in postoperative renal (increased
y 134% in Magano et al5) and cerebrovascular (increased by
15% in Magano et al5) complications in patients receiving apro-
inin compared with control, if they exist.
esults
ix thousand one hundred two patients undergoing CTS
ere evaluated for inclusion into this cohort analysis. Of
hese, 2754 patients had to be excluded from the analysis
ecause they did not receive coronary artery bypass surgery
n  1721) or because their surgeries were conducted
ithout CPB (ie, off-pump surgery; n  1033). Thus, 3348
atients were included in this evaluation, of which 362
atients received aprotinin during surgery (250 of the pa-
ients receiving aprotinin had complex surgeries) and 2986
atients did not.
Patients receiving aprotinin and not receiving aprotinin
aried with respect to a number of important preoperative
nd perioperative characteristics (Table 1). Patients receiv-
ng aprotinin were older, more likely to be undergoing
omplex surgery, and were sicker as evidenced by a more
ignificant history of left main disease, chronic obstructive
ulmonary disease, hypertension, cerebrovascular disease, aor-
ic stenosis, and preoperative renal dysfunction and an in-
reased need for urgent or emergency surgery (P .05 for all).
After multivariate logistic regression including propen-
ity score adjustment, we found that patients receiving apro-
inin were nearly twice as likely to experience postoperative
enal dysfunction (P  .001) but nearly one third less likely
o experience a neurologic complication compared with
ontrol (P  .01), although the decrease in neurologic
omplications with aprotinin was mainly a result in de-
reased delirium (Table 2). No additional differences in
afety end points were noted between aprotinin and control
P  .53 for all comparisons). Patients receiving aprotinin
ere less likely to require a red blood cell transfusion or
eoperation due to bleeding or tamponade compared with
ontrol (P  .001). Aprotinin’s efficacy was mainly a result
f decreased transfusion requirements (P  .001). In all of
hese multivariate analyses, propensity scores were included
s a variable and were never found to be independent
redictors.
and Cardiovascular Surgery ● Volume 133, Number 6 1549
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CSP
When evaluating only patients undergoing complex
TS, increases in postoperative renal dysfunction and de-
reases in the need for red blood cell transfusions, similar to
hose seen in the overall analysis, were observed (P  .024
or both comparisons; Table 3). No other statistically sig-
ificant differences between patients receiving aprotinin or
ontrol were seen in this subgroup analysis.
iscussion
ur study is unique because we utilized data from a US
ospital where (1) the use of aprotinin was restricted pre-
ominantly to complex patients and Jehovah’s Witnesses,
ABLE 1. Pre- and intraoperative patient characteristics
Aprotinin
ge (y, mean  SD)
ale
ace
White
Black
Hispanic
Other
omplex surgery
Valve surgery
Previous cardiothoracic surgery
lective surgery
eft main disease
umber of diseased vessels (mean  SD)
rossclamp time (min, mean  SD) 1
erfusion time (min, mean  SD) 1
atheterization during same admission
istory of diabetes mellitus
istory of chronic obstructive pulmonary disease
istory of hypertension
istory of hyperlipidemia
istory of aortic stenosis
amily history of coronary artery disease
istory of smoking (within 6 mo)
orbidly obese
istory of peripheral vascular disease
istory of cerebrovascular disease
reoperative renal dysfunction
mmunosuppression
rior myocardial infarction
ardiogenic shock
istory of endocarditis
reoperative aspirin use
reoperative anticoagulation use
reoperative digoxin use
reoperative beta-blocker use
reoperative intravenous nitroglycerin
reoperative inotropes
reoperative steroid use
ropensity score (mean  SD)2) there was greater standardization of aprotinin dosing, p
550 The Journal of Thoracic and Cardiovascular Surgery ● Junnd (3) there was no use of celite-ACT determinations,
hich could interact with aprotinin.3,5,9,10 We were not able
o discern elevated odds of developing MIs but found lower
dds of cerebrovascular events and need for red blood cell
ransfusions. In contrast, the previously mentioned multi-
enter observational study found significantly elevated odds
f both cardiac and cerebrovascular events among patients
ndergoing primary surgery.5 Although there were no sig-
ificant elevations in the odds of cardiovascular and cere-
rovascular events among those patients receiving complex
urgery, the odds were about 30% higher for both end points
n their study.5 The type of ACT testing performed in the
(n  362), n (%) Control group (n  2986), n (%) P value
10.4 66.4  10.7 .001
68.5) 2226 (74.5) .01
88.1) 2672 (89.5) .43
1.1) 67 (2.2) .16
2.5) 80 (2.7) .83
8.3) 167 (5.6) .04
69.1) 877 (29.4) .001
47.5) 689 (23.1) .001
34.8) 278 (9.3) .001
56.1) 2107 (70.6) .001
25.4) 624 (20.9) .05
0.75 2.7  0.64 .007
47.8 87.6  40.7 .001
67.7 127.0  50.1 .001
31.8) 1382 (46.3) .001
34.0) 967 (32.4) .54
19.9) 431 (14.4) .006
78.2) 2115 (70.8) .003
70.7) 2019 (67.6) .23
29.6) 317 (10.6) .001
16.6) 712 (23.8) .002
69.6) 2016 (67.5) .42
6.9) 213 (7.1) .87
17.1) 430 (14.4) .17
16.6) 259 (8.7) .001
8.8) 102 (3.4) .001
0.3) 10 (0.3) .99
41.2) 1152 (38.6) .34
1.9%) 47 (1.6) .61
2.8) 17 (0.6) .001
65.5) 2110 (70.7) .04
34.0) 1043 (35.0) .72
9.7) 229 (23.2) .18
76.5) 2289 (76.7) .95
11.3) 397 (13.3) .29
2.5) 48 (1.6) .22
3.6) 150 (5.0) .23
0.21 0.09  0.12 .001group
70.7 
248 (
319 (
4 (
9 (
30 (
250 (
172 (
126 (
203 (
92 (
2.6 
04.9 
55.5 
115 (
123 (
572 (
283 (
256 (
107 (
60 (
252 (
25 (
62 (
60 (
32 (
1 (
149 (
7 (
10 (
237 (
123 (
35 (
277 (
41 (
9 (
13 (revious observational study is not known, but if apprecia-
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CS
Ple utilization of celite-ACTs occurred, this might help to
xplain the qualitative differences between our studies.5 In
single-center observational study conducted in Toronto,
anada comparing propensity score–matched patients re-
eiving either aprotinin (n  449) or tranexamic acid (n 
49), the investigators did not describe what type of ACT
esting occurred but they did show a similar use of heparin
mong groups (50,000  19,000 vs 52,000  14,000 units,
  .10).11 In that study, there was no difference in the
ccurrence of MI or stroke, which is similar to our present
tudy. This suggests even more strongly that a celite-ACT
protinin drug interaction leading to heparin underdosing
ight explain negative thrombotic results in the aforemen-
ioned multicenter observational study.
However, our study and the two previous observational
tudies found a significantly increased risk of renal dysfunc-
ion with aprotinin.5,11 All of our studies used renal dys-
unction as an end point, which could include solely serum
reatinine elevation.5,11 In contrast, the meta-analysis used a
uch more stringent definition of renal failure defined as
nuria, kidney failure, acute kidney failure, kidney tubular
ecrosis, and uremia; which could be an explanation for
ABLE 2. Effect of aprotinin on efficacy and safety end po
ogistic regression in 3348 patients undergoing cardiothor
nd point
ed blood cell use or reoperation due to bleeding/tamponade
Red blood cell use
enal dysfunction
yocardial infarction
eath or hospital readmission
Death
troke, TIA, or delirium
Stroke
TIA
Delirium
IA, Transient ischemic attack. TIA occurred in 0/362 patients treated wit
ABLE 3. Effect of aprotinin on efficacy and safety end
oints as determined by multivariate (propensity score
djusted) logistic regression in 1127 patients undergoing
omplex cardiothoracic surgery
nd point
Total no.
of events
P
value
Odds
ratio
95% confidence
intervals
ed blood cell use or
reoperation due to
bleeding/tamponade
792 .001 0.38 0.27–0.53
enal dysfunction 96 .02 1.76 1.08–2.88
troke, TIA, or delirium 221 .09 0.71 0.48–1.05
yocardial infarction 36 .35 0.65 0.26–1.62pIA, Transient ischemic attack.
The Journal of Thoracichese findings.6 Although some drugs that increase serum
reatinine do indeed increase the risk of renal failure and
ialysis (amphotericin, radiocontrast dye), other drugs such
s angiotensin-converting enzyme inhibitors and angioten-
in receptor antagonists elevate serum creatinine but pro-
ide renal protection secondary to a reduction in glomerular
ltration pressure.12,13
Given the activity of aprotinin on the bradykinin system via
irect inhibition of the serine protease kallikrein (the enzyme
hat converts kininogen to bradykinin),14,15 aprotinin may the-
retically impact serum creatinine through a glomerular filtra-
ion pressure mechanism rather than by causing renal damage.
n addition, aprotinin is primarily metabolized by the proximal
onvoluted tubule and could interfere with the reabsorption of
ther substrates.14 In a study by Fauli and colleagues,16 60
onsecutive patients with normal pre-CTS renal function un-
erwent CTS with CPB. Patients were randomized to placebo,
ow-dose aprotinin, and high-dose aprotinin groups. In this
tudy, the investigators looked at the renal elimination of
lpha-1 microglobulin and beta-glucosamindase post-CTS. Al-
ha-1 microglobulin is a small protein normally glomerularly
ltered and then reabsorbed in the proximal convoluted tubule.
ncreases in alpha-1 microglobulin excretion represent subclin-
cal renal tubular dysfunction without histologic damage. In
ontrast, beta-glucosamindase is a sensitive marker of for ly-
osomal tubular damage indicating renal tubular injury. In the
tudy, alpha-1 microglobulin concentrations were elevated ver-
us placebo but beta-glucosamindase levels were not.16
learly, further work on the mechanism of serum creat-
nine elevation with aprotinin is needed to determine
hether it reflects an increased risk of kidney damage
nd need for dialysis or is just a laboratory anomaly.
tudy Limitations
e acquired our clinical data from the hospital’s CTS
atabase. This database is used for quality control and is a
as determined by multivariate (propensity score adjusted)
surgery
l no. of events P value Odds ratio 95% confidence intervals
1887 .001 0.41 0.31–0.53
1862 .001 0.41 0.32–0.54
182 .001 2.03 1.37–3.01
84 .92 1.04 0.53–2.04
391 .95 1.01 0.71–1.45
202 .53 0.85 0.52–1.40
493 .01 0.65 0.46–0.91
61 .69 0.83 0.33–2.09
8 .82 0.001 0.000–1.6E24
444 .07 0.71 0.49–1.03
otinin patients and 8/2986 control patients.ints
acic
Totaart of the Society of Thoracic Surgery Database. The
and Cardiovascular Surgery ● Volume 133, Number 6 1551
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1
CSPefinitions used were those specified by the Society of
horacic Surgery and were collected using the standard data
xtraction form available at www.sts.org. Researchers were
ot involved in the determination of study end points, and
he care of patients was at the discretion of their clinicians.
lthough this gave investigators less control over the defi-
itions or data extraction, we were not able to introduce
esearcher bias into the trial, and we had prospectively
ollected data entered into the database from which to
erform our data analysis.
In addition, investigators did not have a protocol delin-
ating the standard use of sympathomimetics or the use of
uid resuscitation and could not ensure that the use was
imilar among groups.
onclusions
n many patients undergoing complex CTS surgery without
he use of celite-ACTs, our study suggests that aprotinin use
s not associated with increased odds of cardiovascular or
erebrovascular events but does reduce the need for blood
ransfusion. Further work is needed to understand the im-
lications of the renal dysfunction seen after CTS surgery.
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